Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
about
Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerAddressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancerJohn Fitzpatrick: an appreciation.(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain.Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?Bisphosphonates for advanced prostate cancer.No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer.Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients.Current treatment strategies for advanced prostate cancer.No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer.The Economic Burden of Metastatic Castration Resistant Prostate Cancer and Skeletal Related Events in Japanese University HospitalsRe-emergence of an orphan therapeutic target for the treatment of resistant prostate cancer - a thorough conformational and binding analysis for ROR-γ protein.Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
P2860
Q28079918-75679244-8FB8-4AE3-B632-1BEE66096686Q30244818-68105F33-710F-4DF5-9A38-7E5A83A38382Q30999241-F86B1AC3-0D48-4257-BA03-241773C9AA50Q31108842-F0B29E7A-3FDA-40DD-AF34-E066602170EDQ33701534-0DD4272E-DF41-4DD4-8F08-13943093A3D3Q34614989-5555819D-ECC0-45AE-99E8-2A0EDCF2C8D2Q34960164-AD86F569-5F4F-4776-BEF6-B7078886097BQ34987693-CF7DE71A-162C-4028-B424-D493245AFAD9Q35620225-04C733EB-9A29-498D-9B5D-850AD019E83AQ35890508-1265F1D0-8799-40F6-8479-63411A5C0964Q35965406-F0E5078F-E828-4B61-876F-BE4AE35A175FQ36243639-28ED36DB-36CA-4FD0-8461-8A39BE9EDCEFQ38374885-6069000F-4815-4861-875E-7BE6DBB0DFF9Q38766102-74FEAA3E-EE87-4C3B-9E84-602FEAD2720FQ39189394-DA338878-6479-4860-A435-AC301FA843A8Q39970827-AEE90177-9C2F-4C6D-8EBB-CD7608C90F90Q43211192-961133CD-7E0D-48FE-8546-FB5BACB31DECQ46236637-2904464E-094E-46C4-ABFA-F75282351D05Q47248454-E2BFF294-3B77-4468-9723-FE21200E0193Q48110667-3A5099E6-EE0A-4DAD-A63E-E5AF28D58B04Q48139886-47D91A29-8594-47B1-89DD-A64EFE95F5A9Q48257766-E248EBEE-BECC-4B58-B79B-B2EB213A524EQ48262413-C5CBE6BE-37D4-4482-B3EE-8EF7EF9E99F3Q48311271-F5DB7D46-829E-4348-A346-D7BD368CDE1EQ48332469-297EA86E-0940-4B0F-9301-EA2ACC3F7193Q48561494-41E7C7CC-F290-41FF-BCE0-FE48D9232309Q49593012-C37A4521-5885-4AE3-8FED-410CC7E1AD7BQ49649039-B280DB06-36C4-41B9-B74A-91C7D883C86CQ51232936-09E3A52E-7E6D-4FBE-999D-AB90D3345E9DQ56520077-6E1773CF-E4AE-461E-9114-465A31726575
P2860
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Optimal management of metastat ...... ropean Expert Consensus Panel.
@en
type
label
Optimal management of metastat ...... ropean Expert Consensus Panel.
@en
prefLabel
Optimal management of metastat ...... ropean Expert Consensus Panel.
@en
P2093
P50
P1476
Optimal management of metastat ...... uropean Expert Consensus Panel
@en
P2093
Axel Heidenreich
Bertrand Tombal
Bostjan Seruga
Cora N Sternberg
Craig N Robson
Eleni Efstathiou
Frédéric E Lecouvet
Giuseppe Di Lorenzo
Joaquim Bellmunt
P304
P356
10.1016/J.EJCA.2014.03.010
P577
2014-04-03T00:00:00Z